The concept of immunotherapies dates back to the 18th century; however, since its inception, the field has evolved tremendously and is currently cited as one of the most rapidly growing segments of the pharmaceutical industry. Post the early success of immune checkpoint inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of this market.
The discovery of cancer stems cells (CSCs) may have revolutionized the field of cancer research in a manner similar to how the “germ theory of disease” altered the way medical science looked maladies in general. Before the germ theory, disease and sicknesses were attributed to be manifestations of bad omens and evil spirits. The discovery of
Scientists around the word are debating the scientific and ethical possibilities of using powerful gene editing tools, such as the CRISPR/Cas9 system, to treat heritable diseases in human embryos. In 1987, the discovery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) genes in single celled prokaryotic systems revolutionized genetic engineering. Initially thought to be